BofA Remains Neutral on Bristol-Myers Squibb Company (BMY), Expects Low Single-Digit Growth in the Long Term

Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the 12 deep value stocks to invest in. On November 3, 2025 ...

Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company ...

Bristol-Myers Squibb: Way Too Cheap At 7x P/E

Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...
Forbes

Buy Bristol Myers Squibb Stock At $45?

Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in ...

Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead

Bristol-Myers Squibb Company remains a solid, cash-generative blue-chip stock, with expected slow growth & patience. Learn ...
TipRanks on MSN

Bristol-Myers Squibb’s Earnings Call Highlights Growth and Challenges

Bristol-Myers Squibb Company (($BMY)) has held its Q3 earnings call. Read on for the main highlights of the call.
InvestorsHub on MSN

Bristol-Myers Squibb lifts annual outlook after topping Q3 forecasts

Bristol-Myers Squibb (NYSE:BMY) raised its full-year outlook on Thursday after delivering third-quarter results that exceeded ...